Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7738)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 27, 2020 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Suga T, Sato K, Ohyama T, Matsui S, Kobayashi T, Tojima H, Horiguchi N, Yamazaki Y, Kakizaki S, Nishikido A, Okamura T, Yamada M, Kitamura T, Uraoka T. Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. World J Hepatol 2020; 12(7): 350-362 [PMID: 32821334 DOI: 10.4254/wjh.v12.i7.350] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v12/i7/350.htm |
| Number | Citing Articles |
| 1 |
João Victor Salgado, Miguel Angelo Goes, Natalino Salgado Filho. FGF21 and Chronic Kidney Disease. Metabolism 2021; 118: 154738 doi: 10.1016/j.metabol.2021.154738
|
| 2 |
Suki Ha, Vincent Wai-Sun Wong, Xiang Zhang, Jun Yu. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut 2024; : gutjnl-2024-332398 doi: 10.1136/gutjnl-2024-332398
|
| 3 |
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis. Diabetes, Metabolic Syndrome and Obesity 2024; : 545 doi: 10.2147/DMSO.S448476
|
| 4 |
Zhicheng Gao, Jiaqi Bao, Yilan Hu, Junjie Tu, Lifang Ye, Lihong Wang. Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial
Hypertrophy. Current Drug Targets 2023; 24(13): 1009 doi: 10.2174/1389450124666230907115831
|
| 5 |
Nitin J. Deshmukh, M. S. Kalshetti, Mohan Patil, Pankaj Autade, Ganesh V. Sangle. Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon‐like peptide 1. Clinical and Experimental Pharmacology and Physiology 2024; 51(5) doi: 10.1111/1440-1681.13854
|
| 6 |
Claudia Theys, Dorien Lauwers, Claudina Perez-Novo, Wim Vanden Berghe. PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?. Biomedicines 2022; 10(12): 3041 doi: 10.3390/biomedicines10123041
|
| 7 |
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends in Endocrinology & Metabolism 2022; 33(6): 424 doi: 10.1016/j.tem.2022.03.005
|
| 8 |
Tatjana Radosavljevic, Milica Brankovic, Janko Samardzic, Jasmina Djuretić, Dusan Vukicevic, Danijela Vucevic, Vladimir Jakovljevic. Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches. Antioxidants 2024; 13(8): 906 doi: 10.3390/antiox13080906
|
| 9 |
Milton Packer. Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes. JACC: Heart Failure 2021; 9(8): 535 doi: 10.1016/j.jchf.2021.05.019
|
| 10 |
Milton Packer. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis. Circulation 2022; 146(18): 1383 doi: 10.1161/CIRCULATIONAHA.122.061732
|
| 11 |
Nunzia D'Onofrio, Celestino Sardu, Maria Consiglia Trotta, Lucia Scisciola, Fabrizio Turriziani, Franca Ferraraccio, Iacopo Panarese, Lella Petrella, Mara Fanelli, Piero Modugno, Massimo Massetti, Ludovica Vittoria Marfella, Ferdinando Carlo Sasso, Maria Rosaria Rizzo, Michelangela Barbieri, Fulvio Furbatto, Fabio Minicucci, Ciro Mauro, Massimo Federici, Maria Luisa Balestrieri, Giuseppe Paolisso, Raffaele Marfella. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment. Molecular Metabolism 2021; 54: 101337 doi: 10.1016/j.molmet.2021.101337
|